Accelerating Research to
Transform Human Health

Learn more

About Us

Johnson & Johnson Innovation, JLINX is a multifaceted initiative in Europe designed to identify and nurture early-stage companies who are actively pursuing research with the potential to transform human health.

Accelerating early-stage transformative innovation

We catalyze scientific advances by offering start-ups a spectrum of flexible ways to grow and collaborate across the European life science ecosystem.

Located in a fully dedicated facility on the Janssen Campus in Beerse, Belgium, Johnson & Johnson Innovation, JLINX fosters a creative start-up culture, provides access to select scientific talent and resources on the Janssen Campus and through the Johnson & Johnson Innovation network.

JLINX has a focus on human microbiome research, alongside other areas of innovation in pharmaceuticals and cross-disciplinary healthcare solutions.


Johnson & Johnson Innovation, JLINX is a collaboration between Janssen Pharmaceutica NV and bioqube ventures, which will provide an experienced management team to run the day-to-day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

  • Tom Aelbrecht
    Head of the Janssen Campus Office
  • Debora Dumont
    Managing director of Bioqube Ventures
  • Nico Vandervelpen
    Managing director of Bioqube Ventures


Johnson & Johnson Innovation, JLINX will provides entrepreneurs with opportunities to share ideas and collaborate with each other while accessing a unique combination of resources including investment, infrastructure, and access to relevant internal and external scientific, technical and business expertise.

Operating at the Nexus of Science and Business

JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.

JLINX accelerates early-stage transformative innovation, including a focus on the human microbiome as well as broader life-science research.

Nurtured Independence

Investment in promising transformative innovation through Johnson & Johnson Innovation, JLINX is venture-based and the Johnson & Johnson Family of Companies will not hold any specific rights to commercialized products by virtue of the JLINX relationship.

Johnson & Johnson Innovation will works closely with Bioqube Ventures, which will provide an experienced incubator management team to run day-to-day operations, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

Agility with Scale

Our model combines internal expertise with external entrepreneurial skills creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.

JLINX Community

bioqube.jpg caelus.jpg octimet.jpg s-biomedic.jpg etherna.jpg


  • 1 year of JLINX

    Beerse, Belgium
    April 21, 2017

    Johnson & Johnson Innovation, JLINX (JLINX) is one year old today. With financial support from European (ERDF) and Flemish (VLAIO – Hermes) organisations, JLINX has just expanded its community to seven companies. 

    JLINX was launched in April 2016 by Janssen Pharmaceutica in collaboration with Bioqube Ventures. A new investment and incubation model, JLINX was developed to give a start and support to fledgling companies and projects that have the potential to bring about significant transformations in the field of healthcare. 

  • S-Biomedic joins the JLINX Community

    Beerse, Belgium
    February 9, 2017

    S-Biomedic, an early stage biotech company focused on skin microbiome, has secured financing enabling the company to advance its lead product for acne patients.

    S-Biomedic has developed a method to directly modulate the skin microbiome, with applications in dermatology and the cosmetic industry. The skin microbiome, a habitat of billions of good and bad bacteria, contributes to conditions ranging from acne, eczema and rosacea to ageing. The company was founded by Veronika Oudova, Bernhard Pätzold and Marc Güell and is located at the JLINX facilities in Beerse, Belgium. 

  • Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions

    Cambridge, MA
    February 2, 2017

    Agreements with DayTwo, the Weizmann Institute of Science and Caelus Health Focus on Promoting Health through Microbiome Innovation



Contact Us

Make the Connection

JLINX is open to receive applications. We look forward to discussing opportunities to collaborate with you.

For general inquiries about JLINX, contact:

For investment inquiries, contact:

+32 (0) 14-621-500

Download the Johnson & Johnson
JLINX fact sheet.


Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.